Alzai Health

ALZAI Health Corp. is a Toronto, Ontario, Canada-based healthtech company founded in 2024 that develops an AI-driven Alzheimer's Disease risk screening platform. The company's platform delivers non-invasive, low-cost Alzheimer's risk assessment by analyzing pre-existing biomarker data including demographics and blood panel results already present i... n standard electronic medical records, requiring no new tests or invasive procedures. ALZAI's AI models, trained on real-world patient medical records, flag patients in the early stages of Alzheimer's Disease or at elevated risk of developing it, enabling earlier intervention, treatment, and prevention. The platform serves a range of healthcare stakeholders, with a primary focus on clinical trials companies, where it is used to pre-screen subjects, reduce screen-failure rates, and accelerate participant recruitment. Additional target customers include healthcare providers seeking to integrate Alzheimer's risk screening into routine primary care delivery, public and private payers focused on risk mitigation and care optimization, and individual patients seeking proactive health management. The company's advisory and leadership team includes experienced medical technology executives, a senior neurologist and cognitive neurology specialist from Clalit Health Services in Israel, and a Chief of Biomedical Genetics from Boston University with NIH-funded Alzheimer's genetic risk research. ALZAI Health is venture capital-backed, with Wenova Ventures among its investors, and is currently in IPO registration.Read More